Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091022 · ClinicalTrials.gov registry record · Phase 2
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT04091022 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 64 participants.
The verdict
NCT04091022, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a single institution, randomized, placebo-controlled, double-blind phase IIB trial of 1) topical diclofenac and topical DFMO, or 2) placebo in participants with a history of non melanoma skin cancer/ keratinocytic cancers.
Interventions
- DRUG Solaraze and Vaniqa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2025-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091022
The ClinicalTrials.gov registry entry for NCT04091022 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Solaraze and Vaniqa is the first listed.
NCT04091022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04091022 about?
NCT04091022 is a clinical study titled "Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer". This is a single institution, randomized, placebo-controlled, double-blind phase IIB trial of 1) topical diclofenac and topical DFMO, or 2) placebo in participants with a history of non melanoma skin cancer/ keratinocytic cancers.
What is the current status of trial NCT04091022?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2021-01-18. Estimated completion is 2025-12-11.
What interventions are being tested in trial NCT04091022?
The interventions under investigation include: Solaraze and Vaniqa (DRUG).
Who is sponsoring clinical trial NCT04091022?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.